Modeling and Simulation - PK/PD Archives | Page 19 of 38

Blog

Pediatric Drug Dosing: Tackling Big Problems for Little Patients

The challenges and complexities of pediatric drug development are well recognized. Pharmacometric modeling and simulation (M&S)…

CertaraApril 23, 2015

Publication

Effect of Age and Sex on the Pharmacokinetics and Safety of Avibactam in Healthy Volunteers

Avibactam is a novel non-β-lactam β-lactamase inhibitor currently being assessed in combination with ceftazidime, ceftaroline…

CertaraApril 1, 2015

Publication

Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9

RG7652 is a fully humanized monoclonal antibody targeting human PCSK9, a regulator of serum low…

CertaraMarch 31, 2015

Publication

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-controlled Studies

Avibactam is a novel non-β-lactam β-lactamase inhibitor effective against Ambler class A, C and some…

CertaraMarch 27, 2015

Publication

Pharmacokinetics and Safety of Oseltamivir in Patients with End-stage Renal Disease Treated with Automated Peritoneal Dialysis

CertaraMarch 25, 2015

Publication

Chemotherapy of Second Stage Human African Trypanosomiasis: Comparison Between the Parenteral Diamidine DB829 and Its Oral Prodrug DB868 in Vervet Monkeys

Human African trypanosomiasis (HAT, sleeping sickness) ranks among the most neglected tropical diseases based on…

CertaraFebruary 15, 2015

Blog Knowledge Base

Calculating the Elimination Rate Constant

The elimination rate constant is the rate at which drug is cleared from the body…

CertaraFebruary 2, 2015

Publication

Population Pharmacokinetics of Ceftolozane/Tazobactam in Healthy Volunteers, Subjects with Varying Degrees of Renal Function and Patients with Bacterial Infections

Ceftolozane/tazobactam is a novel antipseudomonal cephalosporin and a β-lactamase inhibitor in clinical development for treatment…

CertaraFebruary 1, 2015

Blog

Common Misconceptions About Computer System Validation

Drug development professionals frequently use computer systems to help them understand the pharmacokinetics (PK) and…

CertaraJanuary 28, 2015

Blog

Using Modeling and Simulation to Quantify the PK of an Anti-HIV Drug for Babies

As a scientist at Certara and proud Dad to my three kids, pediatric drug development…

CertaraJanuary 15, 2015

Modeling and Simulation – PK/PD

Pediatric Drug Dosing: Tackling Big Problems for Little Patients

Effect of Age and Sex on the Pharmacokinetics and Safety of Avibactam in Healthy Volunteers

Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-controlled Studies

Pharmacokinetics and Safety of Oseltamivir in Patients with End-stage Renal Disease Treated with Automated Peritoneal Dialysis

Chemotherapy of Second Stage Human African Trypanosomiasis: Comparison Between the Parenteral Diamidine DB829 and Its Oral Prodrug DB868 in Vervet Monkeys

Calculating the Elimination Rate Constant

Population Pharmacokinetics of Ceftolozane/Tazobactam in Healthy Volunteers, Subjects with Varying Degrees of Renal Function and Patients with Bacterial Infections

Common Misconceptions About Computer System Validation

Using Modeling and Simulation to Quantify the PK of an Anti-HIV Drug for Babies

Newsletter sign up

Quick links

Solutions

Contact